First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Summary

The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.

Timeline

Start

2026-03-09

Primary completion

2028-06

Completion

2029-06

Drugs

Indications